2. Anti-infection
  3. Influenza Virus
  4. Epigoitrin

Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects.

For research use only. We do not sell to patients.

Epigoitrin Chemical Structure

Epigoitrin Chemical Structure

CAS No. : 1072-93-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Epigoitrin:

Epigoitrin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects[1][3].

In Vitro

Epigoitrin (100 μM; 24 h) reduces intracellular triglyceride and total cholesterol levels, increases short-chain acyl-CoA dehydrogenase activity, promotes glucose uptake and glycogen storage, increases ATP production, reduces glutathione content, decreases reactive oxygen species, and enhances superoxide dismutase activity in HepG2 cells[3].
Epigoitrin inhibits the viability of RAW264.7 cells,with an IC50 of 2 mM[2].
Epigoitrin (1-100 μM; pretreated for 2 h, co-treated with Corticosterone (HY-B1618) for 48 h, and infected with H1N1 virus for 1.5 h) shows a dose-dependent inhibition of the mRNA expression of the NP gene in A549 cells compared with untreated cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Epigoitrin Related Antibodies

RT-PCR[1]

Cell Line: Corticosterone-loaded A549 cell.
Concentration: 1 μM, 12.5 μM, 25 μM, 50 μM, 100 μM
Incubation Time: Pretreated for 2 h, co-treated for 48 h
Result: Inhibited the mRNA expression of the NP gene.
In Vivo

Epigoitrin (88-176 mg/kg/d; oral administration; once daily; for 7 consecutive days) reduces the susceptibility of mice to influenza virus in a restraint - stress - induced H1N1 virus - infected mouse model, manifested as reduced mortality, attenuated inflammation, and decreased viral replication in the lungs[1].
Epigoitrin (50-100 mg/kg; added to the feed; for 12 weeks) reduces fat deposition, improves glucose tolerance and insulin sensitivity, and increases energy expenditure in a high-fat diet-induced obese mouse model[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old male C57BL/6J mice were fed a high-fat diet to establish an obesity model[3].
Dosage: 50 mg/kg, 100 mg/kg
Administration: Added to the feed, continuously administered for 12 weeks
Result: Reduced fat deposition in HFD mice.
Reduced adipocyte hypertrophy.
Alleviated hepatic steatosis, as shown by reduced liver lipid droplets and lower liver and serum TG and TC levels.
Had no effect on food intake.
Animal Model: Specific-pathogen-free male Kunming mice (4 weeks of age; 12-15 g) loaded with restraint stress[1]
Dosage: 88 mg/kg, 176 mg/kg
Administration: Oral administration, once daily, for 7 days
Result: Increased the survival rate, prolonged the mean day to death, and reduced the morbidity sign.
Significantly decreased the virus titer in the lungs, reduced the infiltration of inflammatory cells in the lungs, and lowered the levels of TNF-α and IL-1β in bronchoalveolar lavage fluid.
Increased the protein expressions of MAVS, IFN-β, and IFITM3 in the lung tissue, and decreased the protein level of MFN2 and virus nucleoprotein (NP) in stressed mice.
Molecular Weight

129.18

Formula

C5H7NOS
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

S=C1O[C@H](C=C)CN1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (387.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 3.33 mg/mL (25.78 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 7.7409 mL 38.7045 mL 77.4090 mL
5 mM 1.5482 mL 7.7409 mL 15.4818 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (19.35 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (19.35 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.91%

SDS (604 KB)

COA (249 KB) HNMR (197 KB) LCMS (119 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 7.7409 mL 38.7045 mL 77.4090 mL 193.5224 mL
5 mM 1.5482 mL 7.7409 mL 15.4818 mL 38.7045 mL
10 mM 0.7741 mL 3.8704 mL 7.7409 mL 19.3522 mL
15 mM 0.5161 mL 2.5803 mL 5.1606 mL 12.9015 mL
20 mM 0.3870 mL 1.9352 mL 3.8704 mL 9.6761 mL
25 mM 0.3096 mL 1.5482 mL 3.0964 mL 7.7409 mL
DMSO 30 mM 0.2580 mL 1.2901 mL 2.5803 mL 6.4507 mL
40 mM 0.1935 mL 0.9676 mL 1.9352 mL 4.8381 mL
50 mM 0.1548 mL 0.7741 mL 1.5482 mL 3.8704 mL
60 mM 0.1290 mL 0.6451 mL 1.2901 mL 3.2254 mL
80 mM 0.0968 mL 0.4838 mL 0.9676 mL 2.4190 mL
100 mM 0.0774 mL 0.3870 mL 0.7741 mL 1.9352 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Epigoitrin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Epigoitrin1072-93-1Influenza VirusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Epigoitrin
Cat. No.:
HY-N0224
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (604 KB) Français - FR (604 KB) Deutsch - DE (604 KB) Norwegian - NO (604 KB) Español - ES (604 KB) Swedish - SV (604 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.